Novo Nordisk's semaglutide, used in Wegovy and Ozempic, shows promise in reducing liver fat and improving metabolic markers in HIV-related liver disease, according to a mid-stage study. The FLOW kidney outcomes trial also revealed a 24% reduction in kidney disease progression and related deaths with semaglutide treatment. These findings were presented at the Conference on Retroviruses and Opportunistic Infections, highlighting semaglutide's potential benefits for patients with Metabolic dysfunction-associated steatotic liver disease (MASLD).